   
  
G/MA/QR/N/GBR/1/Add.1  
 
24 February 2022  
(22-1804) Page: 1/7 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION  ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
UNITED KINGDOM  
Addendum  
The following communication, dated 24 February 2022 , is being circulated at the request of the 
delegation of the United Kingdom . 
 
A. Notifying Member : United Kingdom  
B. Date of notification : 17 February 2022  
C. First time notification:  
 Yes 
 No, last notification was made in (doc. symbol ): G/MA/QR/N/GBR/1  
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in  G/MA/QR/N/GBR/1  which are of the 
following nature : 
  2.1 Introduction of new restrictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in force as of 
16 December  2021  
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WTO notifications wi th information on quantitative 
restrictions that are currently in force and additional information . 
G. Comments of a general nature, including a description of the elimination of 
restrictions notified under D.2.2 and the date they ceased to be in force.  
1. This addendum modifies G/MA/QR/N/GBR/1 by notifying QR no. 1, which updates and 
replaces QR no. 21 previously notified in Section 1 of G/MA/QR/N/GBR/1.  This notification 
updates the list of commodity codes applicable to the medicines in scope and provides 
further information on how measures are applied.  
 
* In English  only. G/MA/QR/N/GBR/1/Add.1  
 
- 2 - 
 
  2. The UK is notifying the net reduction of 76 medicines from the list of medicines needed to 
support the tre atment of UK patients at a time when COVID -19 is still having a real impact 
on both demand and supply of medicines, the export of which is subject to restriction in 
certain limited circumstances when those medicines are already in the UK supply chain 
and intended for UK patients.  
3. These are temporary measures, in place to relieve critical shortages of medicines 
necessary for the protection of human health. Measures are reviewed regularly and only 
applied where the critical need cannot be met by alternative measures. On 3 August  2021, 
30 medicines were removed from the list. As of 16 December 2021, a further 47 medicines 
were removed from the list. One medicine has been added to the list.  
4. The UK’s notification G/MA/QR/N/GBR/1  included details relating to Nort hern Ireland. This 
notification does not amend those details which continue to apply.  
  
  G/MA/QR/N/GBR/1/Add.1  
 
- 3 - Section 1: List of quantitative restrictions that are currently in force  
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
1 Measures to 
regulate exports of 
certain 
medicaments.  CP-X Medicines fall 
under the 
following 
commodity 
codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.15.00.00  
 1. Heading 3002 - 
Classification  
Human blood; animal 
blood prepared for 
therapeutic, prophylactic 
or diagnostic uses; 
antisera, other blood 
fractions and 
immunological products, 
whether or not modified 
or obtained by means of 
biotechnological 
processes; vacci nes, 
toxins, cultures of micro -
organisms (excluding 
yeasts) and similar 
products; cell cultures, 
whether or not modified  
 
 
 
Product Description per 
Commodity Code under 
Heading 3002  
Immunological products, 
put up in measured 
doses or in forms or 
packings f or retail sale  
 
 Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  
 Regulation 43(2) of 
the Human Medicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so 
that the needs of 
patients in the UK are 
met. Further details 
can be found through: 
https://www.legislatio
n.gov.uk/uksi/2012/1
916/contents/made  
 
The date restrictions 
came into effect varies 
by medicine ; this is 
specified for each 
medicine on the list , 
updated  on 16 
December 2021  and 
available  on gov.uk at  
 
https://assets.publishi
ng.service.gov.uk/gov
ernment/upload s/syst
em/uploads/attachme
nt_data/file/1042790/
restricted -medicines -The list of medicines 
is maintained by the 
Department of Health 
and Social Care.  
 
These measures are 
reviewed regularly.  
A full change log of 
previous measures, 
from October 2019, 
can be found here:  
https://www.go v.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk  
 
Medicines included 
on this list meet the 
following conditions:  
• the medicine is 
required to 
meet the needs 
of UK patients  
• the medicine is 
either being 
exported or is 
at threat of 
being exported   
  G/MA/QR/N/GBR/1/Add.1  
 
- 4 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
list-december -2021-
v3.csv/preview   
 
 
    
 
 
 
 
 
 
 
 
 
 
 2. Heading 3004 - 
Classification  
Medicaments consisting 
of mixed or unmixed 
products for therapeutic 
or prophylactic uses, put 
up in measured doses 
(including those in the 
form of transdermal 
administration systems) 
or in forms or packings 
for retail sale    • the export of 
the medicine is 
either 
contributing to, 
or may 
contribute to, a 
shortage of 
that medicine 
in the UK.  
 
Medicines on this list 
which have been 
produced to fulfil 
contracts overse as 
are not subject to  
    
 
 
3004.20.00  
 
3004.31.00  
3004.32.00  
 
 
 
3004.39.00  
3004.49.00  
 
 Product Description per 
Commodity Code under 
Heading 3004  
Other, containing 
antibiotics  
Containing insulin  
Containing corticosteroid 
hormones, their 
derivatives or structural 
analogues  
Other  
Other  
   restriction. As such, 
restrictions only 
apply to wholesaler 
dealer license holders 
that are not the 
market authorisation 
holder for a medicine 
intended for export. 
The measures are 
designed to ensure 
wholesalers fulfil 
their legal obligations 
to maintain supply to 
UK patients.   
  G/MA/QR/N/GBR/1/Add.1  
 
- 5 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       These restrictions are 
only applied and 
maintained where  
    Further detail of these 
medicines can be found 
at  
https://www.gov.uk/gov
ernment/publications/m
edicines -that-cannot -be-
parallel -exported -from-
the-uk 
 
These restrictions apply 
in certain circumstances 
to exports of specified 
medicines which are 
placed on the UK market 
for UK patients and 
needed to protect human 
health, including to treat 
Covid -19, inter alia.  
 
   alternative measures 
are not considered 
sufficient on their 
own to ensure tha t 
UK supply meets 
demand.  
A number of 
exemptions apply to 
medicines in scope of 
these restrictions. 
For example, exports 
destined for 
international 
humanitarian 
organisations such as 
COVAX are not 
covered. A full list of 
exemptions can be 
found  at 
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk 
 
Requests for 
exemptions are 
considered on a case -  
  G/MA/QR/N/GBR/1/Add.1  
 
- 6 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       by-case basis. These 
can be submitted by 
a foreign government  
or government 
agency, or a 
wholesaler on their 
behalf at 
restrictedmedicines
@dhsc.gov.uk    
 
Further information 
on these measures is 
available here:  
https://www.gov.uk/
guidance/parallel -
export -and-
hoarding -of-
restricted -medicines  
  
It is the responsibility 
of the wholesaler to 
ensure any exports 
are made or withheld 
in compliance with 
these restrictions. 
Failure to comply 
with these 
restrictions may le ad 
to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authority 
(MHRA) against the   
  G/MA/QR/N/GBR/1/Add.1  
 
- 7 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2017)  Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
 
       wholesale dealer’s 
licence.  
There are no 
additional steps or 
declarations required 
from a customs 
perspective.  
 
 
__________  